Please login to the form below
Blue Rubicon
This page shows the latest Blue Rubicon news and features for those working in and with pharma, biotech and healthcare.
Controversial pancreatic cancer campaign wins award
Sainsbury's, Sainsbury's by AMV BBDO, Blue Rubicon, PHD Media and Sainsbury's.
Latest news
-
Blue Rubicon buys Open Road
We're bringing together two independent consultancies with a similar mind-set, approach, reputation and strategic communications offer,” said Blue Rubicon CEO, Gordon Tempest Hay. ... While forming part of the Blue Rubicon family, Open Road will
More from news
Approximately 1 fully matching, plus 1 partially matching documents found.
Latest appointments
-
Firstlight appoints three new directors
All three joined Firstlight having excelled in leading agencies, Sam from Blue Rubicon, Anna from Cohn and Wolfe and Grant from Ruder Finn.
-
Edelman strengthens healthcare team
Dalton moves to the agency from Blue Rubicon, where she was a senior consultant, and also brings experience from Ogilvy &Mather and Weber Shandwick, where she most recently served as an
More from appointments
Approximately 0 fully matching, plus 2 partially matching documents found.
Latest from PMHub
-
Our latest additions
The new team members are:. Sam Bevans With 18 years’ communications experience, including senior roles at freuds and Blue Rubicon, Sam joins Aurora as a Director.
More from PMHub
Approximately 0 fully matching, plus 1 partially matching documents found.
Subscribe to our email news alerts
Featured jobs
- Principal Medical Writer/ Scientific Lead, Medcomms, £5K joining...
-
Highly competitive salary
- Lead Market Access Writer, £5K joining bonus, UK
-
Highly competitive salary
- Exciting Medical Writer Career Opportunity for Postdoc, Medcomms
-
Highly competitive salary
- Market Access Director, six figure base salary and £5K joining b...
-
Highly competitive salary
- Gilead’s CAR-T cell therapy recommended by NICE for lymphoma
- Roche’s Polivy recommended by NICE for lymphoma therapy
- Sanofi/Regeneron’s Dupixent approved by EC for eosinophilic oesophagitis
- ASH 2022: bad blood but big advances
- AbbVie’s Rinvoq approved by MHRA for Crohn's disease
- GSK’s Benlysta given orphan drug status by FDA for systemic sclerosis
- AstraZeneca’s Imfinzi plus chemotherapy approved by MHRA for biliary tract cancer
- ICR calls for improved biomarker cancer tests to help personalise treatment
- EIT Health marks World Cancer Day with €6m pledge for new healthcare delivery models
- World Cancer Day: encouraging men to put their health first
- World Cancer Day 2023 – closing the gaps in cancer care to give more patients access to life-changing medicines
- Strategic behaviour
- AstraZeneca/Daiichi Sankyo’s Enhertu approved by EC for advanced breast cancer
- Creabilis names Catherine Moukheibir as chairman of the board
- World Health Organization releases latest set of COVID-19 guidelines
- FDA and CDC investigate potential safety concern for Pfizer/BioNTech’s COVID-19 vaccine
- Gilead’s CAR-T cell therapy recommended by NICE for lymphoma
- MIT researchers develop AI model to detect future lung cancer risk
PMHub
M3 (EU)
M3 has over 20 years’ experience in building online doctor communities. M3 is the world’s largest network of verified doctors...
Latest intelligence
- World Cancer Day 2023 – closing the gaps in cancer care to give more patients access to life-changing medicines
- Great Expectations – exploring the counterpoint between advances in oncology and the challenges of ensuring life-changing medicines reach patients...
- Strategic behaviour
- Strong strategising depends on your colleagues’ behaviour...
- Pharmaceutical Marketing Strategies For The Digital Age
- In the digital age, a strong digital marketing strategy is crucial for businesses, especially in the highly competitive and complex pharmaceutical industry. There are key trends shaping pharmaceutical marketing, such...
